Ceftizoxime

Summary

Ceftizoxime (CHEMBL528) is an approved small-molecule antibacterial drug (ATC J01DD07); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD07
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 383.4 Da · C13H13N5O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL528
Name	Ceftizoxime
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6533629
ChEBI	CHEBI:553473
ATC	J01DD07
Molecular formula	C13H13N5O5S2
Molecular weight	383.4
InChIKey	NNULBSISHYWZJU-LLKWHZGFSA-N

SMILES: CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O

IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7β-position.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Ceftizoxima, Ceftizoxime, ceftizoxime, CEFTIZOXIME

Parent form; salt/anhydrous children: CHEMBL1201019

Patent coverage: 5,247 distinct patent families (19,912 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Progesterone receptor, Prostaglandin G/H synthase 2, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01347593	PHASE4	COMPLETED	Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).